Industry Pharmaceuticals Trailing Archives - Bartle Doo Article Archives

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, generic pharmaceutical company Mylan has earned a respected four-star ranking.

With that in mind, let’s take a closer look at Mylan and see what CAPS investors are saying about the stock right now.

Mylan facts

Headquarters (founded)	Canonsburg, Pa. (1961)
Market Cap	$11.4 billion
Industry	Pharmaceuticals
Trailing-12-Month Revenue	$6.8 billion
Management	CEO Heather Bresch CFO John Sheehan
Return on Equity (average, past 3 years)	14.7%
Cash/Debt	$409.5 million / $5.7 billion
Competitors	Abbott Labs Teva Pharmaceutical Industries

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 94% of the 569 members who have rated Mylan believe the stock will outperform the S&P 500 going forward.

Earlier this year, one of those Fools, brenoboyle, succinctly summed up the bull case for our community:

Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and [less than] 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Mylan may not be your top choice.

We’ve found another growth play we are incredibly excited about — excited enough to dub it “The Only Stock You Need to Profit from the NEW Technology Revolution.” We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won’t be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Mylan Is Poised to Keep Popping originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
…read more
Source: FULL ARTICLE at DailyFinance

By Brian D. Pacampara, Pacampara, The Motley Fool

Filed under: Investing

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, biopharmaceutical company Optimer Pharmaceuticals has received the dreaded one-star ranking.

With that in mind, let’s take a closer look at Optimer and see what CAPS investors are saying about the stock right now.

Optimer facts

Headquarters (founded)	San Diego, Calif. (1998)
Market Cap	$599.0 million
Industry	Pharmaceuticals
Trailing-12-Month Revenue	$101.5 million
Management	Chairman/CEO Henry McKinnell CFO Stephen Webster
Return on Equity (average, past 3 years)	(47.3%)
Cash/Debt	$124.0 million / $0
Competitors	Bayer Pfizer Sanofi

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 27% of the 149 members who have rated Optimer believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bear case for our community:

Optimer stock is weathering yet another quarter of disappointing Dificid revenues by floating the old “strategic alternatives ” flag. Sometimes the sale happens, more often than not it doesn’t. I remember that tactic didn’t work out very well for [Savient Pharmaceuticals]. Dificid has been a confusing underperformer, given that clostridium difficile infection continues to be a crisis in the US health care system and the available therapeutics are clearly insufficient. Perhaps a larger pharma feels like they have the skills to make Dificid more profitable, but I suspect antibiotics are a relatively low priority for most of those companies. Even if a buyout does occur, I think it will take long enough that most of the short-term momo traders will get bored and exit.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we’ve found another stock we are incredibly excited about — excited enough to dub it “The Motley Fool’s Top Stock for 2013.” We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won’t be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Optimer Pharmaceuticals Is Poised to Pull Back originally appeared on Fool.com.

Bartle Doo Article Archives

Tag Archives: Industry Pharmaceuticals Trailing

Why Mylan Is Poised to Keep Popping

Why Optimer Pharmaceuticals Is Poised to Pull Back

Articles Archive